ClinicalTrials.gg
RecruitingNCT06065306ADD-EDUpdated Oct 22, 2026

Potential Diagnostic Biomarkers for Aortic Dissection in the Emergency Department

An observational study in Aortic Dissection, sponsored by Chinese University of Hong Kong. Recruiting at 1 site in Hong Kong. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Chinese University of Hong Kong · Observational

How we know

From the registry’s dates

  • Started Jun 2023; still recruiting 3 years 5 months later.
Updated Oct 22, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
47
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this observational study is to determine the utility of desmosine, D-dimer and aggrecan as early diagnostic biomarkers in aortic dissection. The main questions it aims to answer are:

  • To investigate the plasma levels of selected biomarkers in ED patients with confirmed aortic dissection
  • To study the diagnostic performance of plasma levels of selected biomarkers for aortic dissection
  • To study the association between plasma levels of selected biomarkers and clinical outcomes
02

Conditions studied

  • Aortic Dissection

Keywords

  • aortic dissection
  • biomarker
  • diagnostic
  • d-dimer
  • aggrecan
  • desmosine
03

In context

Aortic Dissection

206 studies on the registry are indexed under Aortic Dissection; 74 are open to participants now.

This study's planned enrollment of 47 is below the median of 230 across 115 observational studies indexed under Aortic Dissection.

Browse Aortic Dissection studies →

Lead sponsor

Chinese University of Hong Kong is the lead sponsor of 1,458 studies on the registry; 478 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients aged 18 years or above, with AD presenting to the ED within the first 24 hours of symptom onset will be recruited.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Presentation to the ED with first 24 hours of symptoms suggesting AD, including chest pain, upper back pain, syncope of unknown cause, symptoms of any acute perfusion deficit
  • Confirmed AD

    • the diagnosis of AD adjudicated by an independent expert panel at hospital discharge or death, whichever comes first
    • The expert panel will consist of (1) a specialist in Emergency Medicine and (2) a specialist in Cardiology and (3) a specialist in Cardiothoracic Surgery.

Exclusion criteria

Exclusion Criteria:

  • Age \<18 years old
  • Pregnancy
  • Surgery or stenting performed before recruitment
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
47 participants (estimated)
Target follow-up
3 Months
Patient registry
Yes

Groups and cohorts

  • AD

    Patient aged greater than 18, presented to the ED with first 24 hours of symptoms suggesting AD, including chest pain, upper back pain, syncope of unknown cause, symptoms of any acute perfusion deficit and confirmed AD.

  • Healthy

    Patients attending ED who do not have coronary disease, hypertension or aortic disease would be identified as healthy control.

06

What researchers measure

Primary outcomes

  1. Serum levels of D-Dimer, Aggrecan and Desmosine

    Biomarkers :Serum levels of D-Dimer, Aggrecan and Desmosine will be compared in patients with confirmed AD versus age and sex matched healthy controls

    Time frame: Blood samples taken preoperatively

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Dec 2026, 42 months after the start.

Of 48 observational studies under Aortic Dissection, half reached primary completion within 83 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 135. This study's planned 42 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: primary completion Dec 2024 → Dec 2026 and completion Dec 2025 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2023
First posted
Oct 3, 2023
StartActual
Jun 18, 2023
Primary completionEst.
Dec 31, 2026was Dec 2024
CompletionEst.
Dec 31, 2027was Dec 2025
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Prince of Wales Hospital · Shatin, Hong Kong
Show 1 removed
  • Prince of Wales Hospital · Sha Tin, Hong Kong
Oct 22, 2026
Primary completion
Dec 31, 2024→Dec 31, 2026
Oct 22, 2026
Study completion
Dec 31, 2025→Dec 31, 2027
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    1 site added, 1 site removed
    Show site
    • Prince of Wales Hospital · Shatin, Hong Kong
    Show 1 removed
    • Prince of Wales Hospital · Sha Tin, Hong Kong
    Primary completion Dec 31, 2024→Dec 31, 2026
    Study completion Dec 31, 2025→Dec 31, 2027
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06065306
Responsible party
Colin Graham (Professor, Chinese University of Hong Kong) — Principal investigator
First posted
Oct 3, 2023
Start date
Jun 18, 2023
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Oct 22, 2026

Study contacts

Colin A Graham
Contact
cagraham@cuhk.edu.hk
+85235051033
Theresa Hui
Contact
theresahui@cuhk.edu.hk
+85235051698

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion